Everolimus is an inhibitor of the mammalian target of rapamycin . It is a hydroxyethyl ether-substituted derivative of rapamycin with improved pharmacokinetic and pharmacodynamic properties. It inhibits both mTORC1 and mTORC2 complexes by binding to FK506-binding protein , which then binds to mTOR, leading to complex destabilization and blocked kinase function .CANCER RESEARCH· Inhibits cell proliferation, metabolism, and angiogenesis in a variety of cancers using in vitro and in vivo models . IMMUNOLOGY· Acts as an immunosuppressive agent in the context of organ transplantation .
